Skip to content

CIK 0001596783

CTLT Catalent, Inc.

Insider trading from SEC Form 4. Last filing Dec 18, 2024.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
20
with a Form 4 at this company

Signals

Open-market buys and sells at Catalent, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
31WeakMichelle R Ryan
director
sell
$167k
2,800 shares
-21%-
15WeakJoseph Anthony Ferraro
SVP, General Counsel, CCO
sell
$19k
320 shares
-1%-

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Nov 12, 2024 Ryan Michelle R
Director
2,800
0.00% of outstanding
$167kNov 11, 2024none
Oct 18, 2024 Ferraro Joseph Anthony
Officer
320
0.00% of outstanding
$19kOct 18, 2024$36k
Oct 16, 2024 Hawkeswood Thomas W
Officer
625
0.00% of outstanding
$38kOct 16, 2024$37k

Transactions

The last 72 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Dec 18, 2024Steven Barg
director
DDisposition to issuer
Common Stock
-12,374--0Dec 18, 2024
Dec 18, 2024Aristippos Gennadios
Group Pres. Pharma & Consumer
DDisposition to issuer
Common Stock
-113,724--0Dec 18, 2024
Dec 18, 2024David McErlane
Group President, Biologics
DDisposition to issuer
Common Stock
-36,304--0Dec 18, 2024
Dec 18, 2024Michael Hatzfeld
Chief Accounting Officer
DDisposition to issuer
Common Stock
-13,532--0Dec 18, 2024
Dec 18, 2024Scott Gunther
SVP, Quality & Reg. Affairs
DDisposition to issuer
Common Stock
-39,635--0Dec 18, 2024
Dec 18, 2024Joseph Anthony Ferraro
SVP, General Counsel, CCO
DDisposition to issuer
Common Stock
-23,967--0Dec 18, 2024
Dec 18, 2024Jack L Stahl
director
DDisposition to issuer
Common Stock
-47,984--0Dec 18, 2024
Dec 18, 2024Michelle R Ryan
director
DDisposition to issuer
Common Stock
-10,835--0Dec 18, 2024
Dec 18, 2024Stephanie Okey
director
DDisposition to issuer
Common Stock
-12,635--0Dec 18, 2024
Dec 18, 2024Donald E Morel Jr
director
DDisposition to issuer
Common Stock
-70,118--0Dec 18, 2024
Dec 18, 2024Gregory T Lucier
director
DDisposition to issuer
Common Stock
-36,914--0Dec 18, 2024
Dec 18, 2024Frank A Damelio
director
DDisposition to issuer
Common Stock
-12,635--0Dec 18, 2024
Dec 18, 2024Michael J Barber
director
DDisposition to issuer
Common Stock
-18,052--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Common Stock
-177,521--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Common Stock
-29,974--0Dec 18, 2024
Dec 18, 2024Rolf A Classon
director
DDisposition to issuer
Common Stock
-47,984--0Dec 18, 2024
Dec 18, 2024Lisa Evoli
SVP, Chief HR Officer
DDisposition to issuer
Common Stock
-39,366--0Dec 18, 2024
Dec 18, 2024Matti Masanovich
SVP, Chief Financial Officer
DDisposition to issuer
Common Stock
-76,475--0Dec 18, 2024
Dec 18, 2024John J Greisch
Executive Chair
DDisposition to issuer
Common Stock
-79,932--0Dec 18, 2024
Dec 18, 2024J Martin Carroll
director
DDisposition to issuer
Common Stock
-32,734--0Dec 18, 2024
Dec 18, 2024Scott Gunther
SVP, Quality & Reg. Affairs
AGrant or award
Common Stock
+12,938$0.00$012,938Dec 18, 2024
Dec 18, 2024Michael Hatzfeld
Chief Accounting Officer
AGrant or award
Common Stock
+3,144$0.00$03,144Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
AGrant or award
Common Stock
+113,224$0.00$0113,224Dec 18, 2024
Dec 18, 2024Aristippos Gennadios
Group Pres. Pharma & Consumer
AGrant or award
Common Stock
+21,562$0.00$021,562Dec 18, 2024
Dec 18, 2024David McErlane
Group President, Biologics
AGrant or award
Common Stock
+11,426$0.00$011,426Dec 18, 2024
Dec 18, 2024John J Greisch
Executive Chair
DDisposition to issuer
Common Stockindirect: Through John J. Greisch 2014 Trust
-34,000--0Dec 18, 2024
Dec 18, 2024Lisa Evoli
SVP, Chief HR Officer
AGrant or award
Common Stock
+12,032$0.00$012,032Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
AGrant or award
Common Stock
+10,722$0.00$010,722Dec 18, 2024
Dec 18, 2024Matti Masanovich
SVP, Chief Financial Officer
AGrant or award
Common Stock
+71,691$0.00$071,691Dec 18, 2024
Dec 18, 2024Joseph Anthony Ferraro
SVP, General Counsel, CCO
AGrant or award
Common Stock
+14,265$0.00$014,265Dec 18, 2024
Dec 18, 2024John J Greisch
Executive Chair
AGrant or award
Common Stock
+33,530$0.00$033,530Dec 18, 2024
Dec 18, 2024Lisa Evoli
SVP, Chief HR Officer
DDisposition to issuer
Common Stock
-12,032--0Dec 18, 2024
Dec 18, 2024Matti Masanovich
SVP, Chief Financial Officer
DDisposition to issuer
Common Stock
-71,691--0Dec 18, 2024
Dec 18, 2024Joseph Anthony Ferraro
SVP, General Counsel, CCO
DDisposition to issuer
Common Stock
-14,265--0Dec 18, 2024
Dec 18, 2024Scott Gunther
SVP, Quality & Reg. Affairs
DDisposition to issuer
Common Stock
-12,938--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Common Stock
-113,224--0Dec 18, 2024
Dec 18, 2024Aristippos Gennadios
Group Pres. Pharma & Consumer
DDisposition to issuer
Common Stock
-21,562--0Dec 18, 2024
Dec 18, 2024Michael Hatzfeld
Chief Accounting Officer
DDisposition to issuer
Common Stock
-3,144--0Dec 18, 2024
Dec 18, 2024David McErlane
Group President, Biologics
DDisposition to issuer
Common Stock
-11,426--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Common Stock
-10,722--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-11,093--0Dec 18, 2024
Dec 18, 2024John J Greisch
Executive Chair
DDisposition to issuer
Common Stock
-33,530--0Dec 18, 2024
Dec 18, 2024David McErlane
Group President, Biologics
DDisposition to issuer
Option to purchase Common Stockderivative
-14,740--0Dec 18, 2024
Dec 18, 2024Lisa Evoli
SVP, Chief HR Officer
DDisposition to issuer
Options to purchase Common Stockderivative
-14,225--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-1,550--0Dec 18, 2024
Dec 18, 2024Matti Masanovich
SVP, Chief Financial Officer
DDisposition to issuer
Options to purchase Common Stockderivative
-81,082--0Dec 18, 2024
Dec 18, 2024John J Greisch
Executive Chair
DDisposition to issuer
Options to purchase Common Stockderivative
-127,096--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-10,375--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-2,622--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-10,523--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-3,650--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-13,735--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-3,055--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-15,395--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-2,565--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-15,568--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-2,828--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-44,427--0Dec 18, 2024
Dec 18, 2024Ricky Hopson
Pres. BioProduct Delivery, CoS
DDisposition to issuer
Options to purchase Common Stockderivative
-10,669--0Dec 18, 2024
Dec 18, 2024Alessandro Maselli
President & CEO
DDisposition to issuer
Options to purchase Common Stockderivative
-103,360--0Dec 18, 2024
Nov 11, 2024Michelle R Ryan
director
SOpen-market sale
Common Stock
-2,800$59.70$167k10,835Nov 14, 2024
Oct 30, 2024Michael J Barber
director
AGrant or award
Common Stock
+4,663$0.00$018,052Nov 1, 2024
Oct 30, 2024Steven Barg
director
AGrant or award
Common Stock
+4,663$0.00$012,374Nov 1, 2024
Oct 30, 2024J Martin Carroll
director
AGrant or award
Common Stock
+4,663$0.00$032,734Nov 1, 2024
Oct 30, 2024Rolf A Classon
director
AGrant or award
Common Stock
+4,663$0.00$047,984Nov 1, 2024
Oct 30, 2024Jack L Stahl
director
AGrant or award
Common Stock
+4,663$0.00$047,984Nov 1, 2024
Oct 30, 2024Gregory T Lucier
director
AGrant or award
Common Stock
+4,663$0.00$036,914Nov 1, 2024
Oct 30, 2024Donald E Morel Jr
director
AGrant or award
Common Stock
+4,663$0.00$070,118Nov 1, 2024
Oct 30, 2024Frank A Damelio
director
AGrant or award
Common Stock
+4,663$0.00$012,635Nov 1, 2024
Oct 30, 2024Stephanie Okey
director
AGrant or award
Common Stock
+4,663$0.00$012,635Nov 1, 2024
Oct 30, 2024Michelle R Ryan
director
AGrant or award
Common Stock
+4,663$0.00$013,635Nov 1, 2024
Oct 18, 2024Joseph Anthony Ferraro
SVP, General Counsel, CCO
SOpen-market sale
Common Stock
-320$59.97$19k23,967Oct 21, 2024

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

CTLT insider trading: Catalent, Inc. | InsiderTell